Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 290, Issue 2, 2006, Pages

  Portik Dobos, Vera ^c   Harris, Alex K ^c   Song, Weiwei ^a   Hutchinson, Jimmie ^a   Johnson, Maribeth H ^b   Imig, John D ^b   Pollock, David M ^b   Ergul, Adviye ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Clinical Pharmacy CJ 1020 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GELATINASE A; GELATINASE B; GROWTH PROMOTOR; MATRIX METALLOPROTEINASE; EGFR PROTEIN, RAT; ENDOTHELIN; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOBLOTTING; KIDNEY INJURY; KIDNEY MEDULLA; KIDNEY STRUCTURE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STAINING; TRANSACTIVATION; UPREGULATION; ZYMOGRAPHY; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; KIDNEY; METABOLISM; PHOSPHORYLATION; RAT STRAIN;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENDOTHELINS; FIBRONECTINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; KIDNEY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PHOSPHORYLATION; PYRROLIDINES; RATS; RATS, INBRED STRAINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANS-ACTIVATION (GENETICS);

EID: 33644871367     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00300.2005     Document Type: Article

References (46)

1. Amiri F, Venema VJ, Wang X, Ju H, Venema RC, and Marrero MB. Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem 274: 32382-32386, 1999.
2. American Diabetes Association. National diabetes fact sheet. http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet.jsp, 2002.
3. Conover W and Iman R. Rank transformations as a bridge between parametric and nonparametric statistics. Am Stat 35: 124-133, 1981.
4. Cooper ME, Bonnet J, Oldfield M, and Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens 14: 475-486, 2001.
5. Cooper ME, Gilbert RE, and Jerums G. Diabetic vascular complications. Clin Exp Pharmacol Physiol 24: 770-775, 1997.
6. Cosenzi A, Bernobich E, Trevisan R, Milutinovic N, Borri A, and Bellini G. Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 42: 752-756, 2003.
7. Dhein S, Hochreuther S, Aus Dem Spring C, Bollig K, Hufnagel C, and Raschack M. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 293: 351-359, 2000.
8. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, and Clozel M. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 42: 48-54, 2003.
9. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, and Fuchs LC. Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol 285: H2225-H2232, 2003.
10. Ergul S, Parish CD, Puett D, and Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28: 652-655, 1996.
11. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, and Dussaule JC. Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 17: 327-329, 2003.
12. Gibson S, Tu S, Oyer R, Anderson SM, and Johnson GL. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274: 17612-17618, 1999.
13. Gilbert RE, Cox A, McNally PG, Wu LL, Dziadek M, Cooper ME, and Jerums G. Increased epidermal growth factor in experimental diabetes-related kidney growth in rats. Diabetologia 40: 778-785, 1997.
14. Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F, Bauer C, Neumayer HH, and Raschack M. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 87: 161-169, 2001.
15. Ishikawa Y, Asuwa N, Ishii T, Ito K, Akasaka Y, Masuda T, Zhang L, and Kiguchi H. Collagen alteration in vascular remodeling by hemodynamic factors. Virchows Arch 437: 138-148, 2000.
16. Itoh Y, Imamura S, Yamamoto K, Ono Y, Nagata M, Kobayashi T, Kato T, Tomita M, Nakai A, Itoh M, and Nagasaka A. Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate. J Endocrinol 175: 233-239, 2002.
17. Jandeleit-Dahm K, Allen TJ, Youssef S, Gilbert RE, and Cooper ME. Is there a role for endothelin antagonists in diabetic renal disease? Diab Obes Metab 2: 15-24, 2000.
18. Janssen U, Vassiliadou A, Riley SG, Phillips AO, and Floege J. The quest for a model of type II diabetes with nephropathy: the Goto Kakizaki rat. J Nephrol 17: 769-773, 2004.
19. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, and Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 61: 31-39, 2002.
20. McLennan SV, Fisher E, Martell SY, Death AK, Williams PF, Lyons JG, and Yue DK. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int 58: S81-S87, 2000.
21. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, and Gilbert RE. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45: 268-275, 2002.
22. McLennan SV, Martell SK, and Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 51: 2612-2618, 2002.
23. McLennan SV, Martell SY, and Yue DK. High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation. Diabetologia 43: 642-648, 2000.
24. McLennan SV, Wang XY, Moreno V, Yue DK, and Twigg SM. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145: 5646-5655, 2004.
25. Mishra R, Leahy P, and Simonson MS. Gene expression profile of endothelin-1-induced growth in glomerular mesangial cells. Am J Physiol Cell Physiol 285: C1109-C1115, 2003.
26. Nagase H and Woessner JF. Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999.
27. Norman J, Tsau YK, Bacay A, and Fine LG. Epidermal growth factor accelerates functional recovery from ischaemic acute tubular necrosis in the rat: role of the epidermal growth factor receptor. Clin Sci (Lond) 78: 445-450, 1990.
28. Oh JH, Ha H, Yu MR, and Lee HB. Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney Int 54: 1872-1878, 1998.
29. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, and Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51: 3063-3068, 2002.
30. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, and Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888, 1999.
31. Riser BL and Cortes P. Connective tissue growth factor and its regulation: a new element in diabetic glomerulosclerosis. Ren Fail 23: 459-470, 2001.
32. Riser BL, Cortes P, DeNichilo M, Deshmukh PV, Chahal PS, Mohammed AK, Yee J, and Kahkonen D. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 64: 451-458, 2003.
33. Saito S, Frank GD, Motley ED, Dempsey PJ, Utsunomiya H, Inagami T, and Eguchi S. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 294: 1023-1029, 2002.
34. Sato N, Komatsu K, and Kurumatani H. Late onset of diabetic nephropathy in spontaneously diabetic GK rats. Am J Nephrol 23: 334-342, 2003.
35. Schrijvers BF, De Vriese AS, Van de Voorde J, Rasch R, Lameire NH, and Flyvbjerg A. Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes. Nephrol Dial Transplant 19: 1092-1097, 2004.
36. Seyer-Hansen K. Renal hypertrophy in experimental diabetes mellitus. Kidney Int 23: 643-646, 1983.
37. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, and Marrero MB. High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 278: 30634-30641, 2003.
38. 1. Exp Nephrol 9: 249-257, 2001.
39. Song RH, Singh AK, and Leehey DJ. Decreased glomerular proteinase activity in the streptozotocin diabetic rat. Am J Nephrol 19: 441-446, 1999.
40. Sorokin A and Kohan DE. Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 285: F579-F589, 2003.
41. Sugimoto K, Tsuruoka S, and Fujimura A. Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats. Eur J Pharmacol 450: 183-189, 2002.
42. Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, Amano K, Higashiyama S, and Iwasaka T. Involvement of HB-EGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int 62: 799-808, 2002.
43. Visse R and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
44. Wassef L, Kelly DJ, and Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 66: 1805-1814, 2004.
45. Williams JM, Pollock JS, and Pollock DM. Arterial pressure response to the antioxidant tempol and ETB receptor blockade in rats on a high-salt diet. Hypertension 44: 770-775, 2004.
46. Yao J, Morioka T, Li B, and Oite T. Endothelin is a potent inhibitor of matrix metalloproteinase-2 secretion and activation in rat mesangial cells. Am J Physiol Renal Physiol 280: F628-F635, 2001.